Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2018-02-22 13:56 CET (UTC+1h)

Highly Variable Drug BE Justification [Regulatives / Guidelines]

posted by ElMaestro - Denmark, 2017-03-20 06:55  - Posting: # 17167
Views: 6,232

Hi jag009,

» What if one conducted pilot studies and found that the ISCV is like 28/29%? My concensus still would be to proceed with RSABE approach since the it is a mixed approach which allows both RSABE(if Ref SD<0.294) and ABE analysis(if Ref SD>0.294)

That's valid, but if you are not really sure if you are just "borderline" then the additional overhead associated with the replicated design may not be worth it. You find an intra-CVR of 31%, and you scale the limits a wee bit etc. But the price you paid for this moderate scaling option could be much higher than you'd be paying for a conventional 222BE trial with a few extra volunteers. Would be interesting to discuss an objective function here :-)

This isn' the answer, but just a view.

I could be wrong, but…

Best regards,

- Bootstrapping for dissolution data is a relatively new hobby of mine.

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
17,931 Posts in 3,818 Threads, 1,120 registered users;
37 users online (1 registered, 36 guests).

When people learn no tools of judgment
and merely follow their hopes,
the seeds of political manipulation are sown.    Stephen Jay Gould

BEBAC Ing. Helmut Schütz